Pfizer challenges Roche blockbusters with 3 biosim launches at discounts from 22% to 24%

Pfizer  headquarters logo sign
Pfizer is in the process of launching biosims to three Roche cancer blockbusters. (Tracy Staton)

Pfizer hit some unexpected roadblocks with its first U.S. biosimilar launch, but it’s not giving up in the budding field. Now, the drugmaker is launching biosims to three Roche cancer blockbusters at discounts ranging from 22% to 24%.  

The company has already rolled out Zirabev and Ruxience, its biosimilars to Roche’s Avastin and Rituxan, respectively, at discounts of 23% and 24%. On February 15, it’s planning to launch Herceptin biosimilar Trazimera at a 22% discount, the company said Thursday. 

All three Roche meds are already facing U.S. biosimilar competition and pulled in more than $10 billion combined at peak. For its part, Pfizer says it’ll be the first company to market three oncology monoclonal antibody biosimilars in the U.S. 

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

The drugmaker has been active in the U.S. biosim market, starting with its Inflectra launch in October 2016. That copycat to Johnson & Johnson’s blockbuster immunology med Remicade hit the market at a 15% discount and couldn’t gain traction against the entrenched competition. 

RELATED: With its Remicade biosimilar stymied by the brand, Pfizer sues Johnson & Johnson for 'anticompetitive' dealmaking

Pfizer later sued J&J for making “anticompetitive” deals with payers that blocked out biosimilar competition. Pfizer said J&J tied Remicade’s rebates to the stipulation that payers don’t use biosimilars, while J&J hit back that Pfizer hadn't offered enough value to win business.

U.S. sales for Inflectra have picked up somewhat and reached $208 million in the first nine months of 2019. Still, that's compared to a much bigger $2.32 billion haul for Remicade over the same span.  

RELATED: Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market

Since that rollout, Pfizer has also launched Retacrit, a biosim to J&J’s Procrit and Amgen’s Epogen. That copycat hit the market in November 2018 at a 33% discount. On an October conference call, Pfizer’s biopharma chief Angela Hwang said Retacrit had nabbed 16% of market share, the most of any biosim in the U.S.  

That experience has “given us the opportunity to learn about what it will take to launch oncology biosimilars as well as what we can expect in this particular space," she said on the call. 

Pfizer will be entering a competitive market with its newest biosims. Roche's Rituxan already faces competition from the Teva-Celltrion team, while Avastin is facing off against a copycat from Amgen and Allergan. Herceptin faces competition from that same Amgen-Allergan duo, plus another in Mylan-Biocon.

Read more on

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.